Intergroup on Cancer & Rare Diseases – Report on Strasbourg Hearing on the Pharmaceutical Legislation

The European Parliament’s Intergroup on Cancer and Rare Diseases official report of its high-level hearing on the revision of the EU Pharmaceutical Legislation is out. The document summarizes the high-level discussion convened at the Intergroup Hearing held on July 10 in the European Parliament, Strasbourg.

Taking place at a crucial stage in the legislative process, as trilogue negotiations advance, the event brought together policymakers, patients, clinicians, and industry representatives to discuss how the new legislation can better serve people living with cancer, rare diseases and childhood cancer.  The hearing reflected a collective call to ensure that the revised pharmaceutical legislation delivers on its promise: to serve patients' real needs through smarter incentives, inclusive governance, and a steadfast focus on public health outcomes.

Key topics discussed included regulatory incentives for innovation to better address unmet medical needs, the specific case of a First-in-Child incentive, a patient-centred approach in the EMA governance, support for non-commercial research, and fair access across Member States. The discussion and policy recommendations arising from the Hearing are available in the report.

🔗 Read the full Hearing Report